You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


UK approval for Epidyolex to treat seizures from tuberous sclerosis

Jazz Pharmaceuticals subsidiary GW Pharmaceuticals has received approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for its cannabidiol Epidyolex as an adjunctive treatment of seizures associated with tuberous sclerosis complex (TSC), for patients aged two years and older.